Patients presenting with DVT in the absence of any identifiable risk factors are said to have an unprovoked or idiopathic DVT. Recurrent events are much more common in these patients (10% vs. 3% at 1 year) compared to patients with a DVT provoked by a reversible risk factor, and represents a major healthcare problem. 1 Three months of anticoagulation is sufficient to decrease the risk of recurrent thrombosis related to the initial DVT. However, once therapy is discontinued, the risk for recurrence rises dramatically. It has been suggested that 30 to 50% of patients experience a recurrence at 10 years. 2, 3 Factors associated with a higher likelihood of recurrence are male gender, elevated D dimer, incomplete resolution of DVT, body mass index 30, and post-thrombotic syndrome. 4 In fact, a number of tools have been developed to determine the risk of recurrence after DVT.
In the current management paradigm, patients with unprovoked DVT are evaluated for long term anticoagulation following initial treatment with 3-6 months of anticoagulation. The risks of major bleeding during prolonged therapy are periodically weighed against the benefits of continuing anticoagulation in high-risk patients. Data supporting this approach comes from 4 studies demonstrating a decreased in recurrent VTE by 90% with extended conventional dose VKA therapy. 5 Major bleeding occurs in 20 per 1000 patients, and as of yet no validated prediction tool exists to predict risk-benefit ratio of extended therapy. 6 Factors associated with an increased risk of bleeding include advanced age > 75, history of gastrointestinal bleeding, non-cardioembolic stroke, renal or hepatic disease, concomitant antiplatelet usage, and poor control of anticoagulation. 5 In the interest of diminishing the bleeding risk while conferring protection against recurrent venous thromboembolism several approaches have been taken: subtherapeutic anticoagulation with vitamin K antagonists (VKA), new oral anticoagulant agents and aspirin. 7 he risk of recurrence after DVT.
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Despite universal availability, inexpensive cost and well-established drug safety profile, the use of aspirin previously has not been extensively studied outside of the orthopedic surgery beyond initial anticoagulation. [9] [10] [11] (Table 1) In a pooled meta-analysis of the dat ata a a, N N NOA OA OACs Cs Cs decreased the risk of recurrent VTE or VTE-related death by 84% with a number needed to treat N NNT NT NT) ) ) of of of 1 1 17 7 7 c comp mp mpar a ed to placebo. 12 The Aspirin for the prevention of recurrent venous thromboembolism study (INSPIRE) 15 was designed to more accurately delineate the treatment effects of the WARFASA and ASPIRE trials in pre-specified subgroups by combining the results at a patient level prior to unbinding of the two arms. The study, initially powered to detect with 80% confidence a 30% reduction in recurrent VTE, although due to slow enrollment, was ultimately powered to detect a 35% reduction in recurrent VTE. VTE occurred in 18.4% of patients on placebo and in 13.1% of patients assigned to aspirin (HR 0.68, CI 0.51 to 0.90, p=0.008) corresponding to a NNT of 42 to prevent one symptomatic VTE occurrence. Additional data garnered from this analysis was most valuable in identifying the populations most likely to benefit (men and individuals aged 65) and evaluating the treatment effect over time. The absolute reduction of recurrent events was significantly greater over the first year when the risk of recurrence was highest.
It is surprising, given that platelets are known to be central to thrombosis, that antiplatelet therapy was not considered sooner to be compared in a rigorous randomized control trial for detect moderate treatment effects amongst different subgroups of patients.
The Aspirin for the prevention of recurrent venous thromboembolism study (INSPIRE) 15 wa was s s was generally lacking. One early report with an experimental rodent model suggests platelets directly contributed to acute venous thrombosis, 16 but most experimental venous thrombosis research over the last two decades has focused on the role of the leukocyte and vein wall. 17, 18 This is because of the classic dogma that the fibrin rich 'red clot' formation in venous thrombosis is primarily driven by the clotting pathway, while arterial thrombosis is thought to be more platelet driven. However, recent experimental data using murine models suggests that the platelet is a critical component of early DVT. First, the assembling and co-localization of the coagulation cascade occurs on the platelet surface in juxtaposition to the endothelium. 19 Second, release of von Willebrand Factor (vWF) provides a bridge between the platelet and endothelium. Studies using vWF gene deleted mice confirmed decreased thrombus size that was not reversed with exogenous factor VIII, in a flow limited venous thrombosis model. 20 Extrapolation of data to humans is somewhat limited with any animal model system of human disease, including partial or total stasis DVT models. 21 Particularly relevant to the current INSPIRE study is that there are no animal models (yet) of recurrent DVT.
The pathophysiology of recurrent unprovoked DVT may be different than primary DVT.
How? It is likely the vein wall is damaged with the initial thrombus insult, even in those who How to take this information and make current recommendations? (Figure 1) We would suggest that for patients who have unprovoked (idiopathic) VTE and are at high risk for recurrence and would normally need long-term or life-long anticoagulation, they remain on either oral vitamin K antagonists or one of the new oral anticoagulant agents and not undergo aspirin therapy. On the other hand, for patients with unprovoked VTE and moderate risk for recurrence, the use of one aspirin per day rather than nothing would be would be indicated. For those patients with an unprovoked VTE and low risk for recurrence, no further therapy is indicated. For patients with a provoked VTE, a total of 3 months of anticoagulation is indicated.
Many questions remain and are not answered from the current data, including:
1.
Is there an optimal length of aspirin therapy in patients with unprovoked VTE and a moderate risk for recurrence?
2.
Should aspirin be used in those patients with unprovoked VTE and low risk for recurrence?
3.
For patients with a provoked VTE would normally would not need long-term anticoagulation (a patient with a first episode of VTE and a cause which has reversed such as VTE associated with surgery or with the use of oral contraceptives), is taking one aspirin per day at the end of a full course of anticoagulation beneficial?
4.
Will other medications such as statins synergize with aspirin to reduce the incidence of recurrent VTE?
5.
Will the more potent antiplatelet theinopyridines be more or less effective than aspirin? Finally, will the current data on only a little over 1200 patients hold up in day to day clinical use?
As is the case with all good studies, more questions remain to be answered and are the seeds for future studies. 
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